V
Valink Therapeutics
Biotech & Life Sciences · London, United Kingdom · Founded 2021
Creating custom biologics using a modular approach MoreLess
Valink Therapeutics is a biotechnology company specializing in the development of bispecific antibody drug conjugates for the treatment of solid tumors. The company leverages its proprietary 5D Combinatorial Drug Discovery Platform to rapidly design and build libraries of drug candidates using modular components such as antibody fragments and small molecules. This approach allows for the creation of next-generation cancer treatments that are both specific and effective, targeting two cellular markers simultaneously to distinguish malignant from healthy tissue. Valink Therapeutics serves the oncology market, focusing on providing innovative solutions for cancer treatment. The business model involves the development and commercialization of these advanced therapeutics, generating revenue through partnerships, licensing agreements, and direct sales.
Keywords: bispecific antibodies, drug conjugates, solid tumors, cancer treatment, modular design, 5D platform, oncology, biotechnology, rapid drug design, antibody engineering.
Company overview
Valink Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- London, United Kingdom
- Employees
- 32
- Open positions
- 1
- Dealroom signal
- 88.7
Valuation & funding
Valink Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2025 | $12M | $46M | Hoxton Ventures · Redalpine · Oxford Science Enterprises · RV Invest | ↗ |
| EARLY VC✓Equity / VC | Aug 2025 | $10M | $41M | Undisclosed | ↗ |
| SEED✓Equity / VC | Nov 2023 | $8.3M | $33M | Hoxton Ventures · Y Combinator · MetaPlanet · RV Invest | ↗ |
| SEED✓Equity / VC | Mar 2021 | $125K | $500K | Y Combinator | — |
| SPINOUT✓Other financing | Jan 2021 | $0 | — | University of Oxford · Oxford University Innovation | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $500K | 0% | 31 |
| 2025 | $500K | 0% | 28 |
| 2024 | $500K | 0% | 17 |
| 2023 | $500K | — | 12 |
Growth signals
Valink Therapeutics website traffic
Latest recorded traffic for Valink Therapeutics is 1.8K monthly website visits, up 12.5% over the last three months. Valink Therapeutics's team grew 14.3% over the past year.
Comparisons
Valink Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Valink Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Valink Therapeutics has talent and traffic
team presence
In the news
Latest news about Valink Therapeutics
Recent press, funding announcements, and product moves mentioning Valink Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Valink Therapeutics
An AI-synthesized read of the highest-engagement posts about Valink Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Valink Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.